Anonymous
Guest
Anonymous
Guest
Seems like the value proposition of this test is pretty good in select cases. Why is it not successful? What are urologist saying about it? What are the reason's they use it? and what are the reasons they don't?
If you have been in sales for any amount of time, you know "I'm not interested.." is just the beginning of the real conversation. .
Okay.. but why are they not interested? If you have been in sales for any amount of time, you know "I'm not interested.." is just the beginning of the real conversation. I'm looking to understand the specific reasons urologist are or are not using the test. ( because I may be interviewing with PBS.)
If I'm correct your company claims that in its studies, 7% of patients with unexplained hematuria and a negative cystoscopy had bladder cancer which was detected by your test...Is that right?
If that is correct, I don't understand why a company like Know Error can be successful and PBS is having problems. Know Error has been successful in providing a solution to a problem that only impacts 1% of patients who receive a prostate biopsy. So why is this test having adoption issues when it has the potential to uncover a significant number of patients who may have otherwise gone improperly diagnoised?
Serious replies only please.